Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Qizhou Ziyue Biotechnology Co. Ltd. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, KIEFER, DALTON EDWARD, who is the busiest examiner with 1 busiest examiner pending action. The portfolio is focused within 1 distinct art unit, reflecting a specific area of biological innovation.
For a practitioner, the prosecution of the entire pending portfolio is currently a matter of addressing the requirements of KIEFER, DALTON EDWARD. The concentration in 1 distinct art unit allows for a very targeted legal and technical strategy. Since there is only 1 pending office action, the practitioner can dedicate full attention to this single matter.
However, the lack of diversity in examiners means there is no way to hedge against the specific examination habits of a single individual. The 1 busiest examiner pending action indicates that the examiner's attention is not divided among multiple cases for this specific company. Success in the Biotechnology & Pharmaceuticals field for this portfolio depends on navigating the specific standards of the 1 distinct art unit involved.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KIEFER, DALTON EDWARD | 1 | 85.7% | +16.7% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18834233 | D-AMINO ACID OXIDASE AND USE THEREOF IN PREPARATION OF L-PHOSPHINOTHRICIN OR INTERMEDIATE THEREOF | KIEFER, DALTON EDWARD | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18834233 | D-AMINO ACID OXIDASE AND USE THEREOF IN PREPARATION OF L-PHOSPHINOTHRICIN OR INTERMEDIATE THEREOF | KIEFER, DALTON EDWARD | — |
| Art Unit | Apps |
|---|---|
| 1652 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18834233 | D-AMINO ACID OXIDASE AND USE THEREOF IN PREPARATION OF L-PHOSPHINOTHRICIN OR INTERMEDIATE THEREOF | KIEFER, DALTON EDWARD | 1652 | §112 | Non-Final OA | — | Pending | Jul 30, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShanghai Qizhou Ziyue Biotechnology Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Dalton Edward Kiefer has the most, with 1 of Shanghai Qizhou Ziyue Biotechnology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
